Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer

Last updated: August 7, 2024
Sponsor: Kong Fanming
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lung Cancer

Cancer

Non-small Cell Lung Cancer

Treatment

Transcutaneous Acupoint Electrical Stimulation (TAES)

Clinical Study ID

NCT06548711
TYLL2024[Z]026
  • Ages 18-80
  • All Genders

Study Summary

Observation and exploration of the improvement in cough symptoms in postoperative lung cancer patients with Transcutaneous Acupoint Electrical Stimulation (TAES), the change in Cough Symptom Score (CSS) compared to baseline, the change in Visual Analog Scale (VAS) score for cough symptoms compared to baseline, the change in total score of Leicester Cough Questionnaire-Mandarin Chinese version (LCQ-MC) compared to baseline, and overall evaluation of treatment effectiveness by patients. A total of 120 postoperative lung cancer patients with cough were strictly selected according to the inclusion/exclusion criteria and treated and followed up according to the research plan requirements. Clinical observation forms were completed and clinical data were recorded in the database. Statistical analysis was performed on relevant clinical observation indicators to report research results and write related papers.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age between 18 and 80 years old - Surgery performed under general anesthesia forradical resection of lung cancer or lung cancer resection combined with lymph nodedissection.

  • Pathological confirmation of primary lung cancer after surgery.

  • Duration of persistent dry cough after lung surgery ≥2 weeks.

  • Consciousness, ability to express opinions clearly, and voluntary signing ofinformed consent.

Exclusion

Exclusion Criteria:

  • Patients diagnosed with acute respiratory system diseases within 1 month.

  • Patients diagnosed with pneumonia based on chest X-ray.

  • Patients with a history of asthma or tuberculosis.

  • Patients with uncontrolled hyperthyroidism, severe hypertension, heart disease,systemic infection, coagulation disorders (hypercoagulable state or bleedingtendency), or other severe systemic diseases.

  • Patients who have used steroid drugs within the past 3 months.

  • Patients who have taken angiotensin-converting enzyme inhibitors (ACEIs) within thepast 6 months.

  • Patients with surgical incisions, skin allergies, wounds, or infections in thetreatment area.

  • Patients who cannot tolerate transcutaneous acupoint electrical stimulation orwithdraw during the procedure.

  • Patients with contraindications to transcutaneous electrical stimulation orimplanted electrophysiological devices.

  • Patients who are pregnant or breastfeeding.

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Transcutaneous Acupoint Electrical Stimulation (TAES)
Phase:
Study Start date:
April 17, 2024
Estimated Completion Date:
June 17, 2026

Study Description

To obtain sufficient evidence from evidence-based medicine, prospective, random, blind, and controlled clinical trials are adopted to evaluate the effectiveness and safety of TEAS in treating postoperative cough in lung cancer patients. This study aims to provide a potential non-pharmacological treatment option for postoperative cough patients with lung cancer, improve the quality of life of postoperative lung cancer patients, identify the population that is more likely to benefit from TEAS treatment and provide a solid scientific basis and guidance for personalized acupuncture treatment for postoperative cough in lung cancer patients.

Connect with a study center

  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

    Tianjin, Tianjin 300193
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.